Narcolepsy Treatment Market By Type of Disorder (Secondary Narcolepsy, Narcolepsy with cataplexy, Narcolepsy without cataplexy), By Drugs (Amphetamines, Methylphenidate, Modafinil, MAO-B Inhibitors (Selegiline), Tricyclic Anti-Depressants (TCA), Selective Serotonin Reuptake Inhibitors (SSRI), Monoamine Oxidase Type-A (MAO-A) inhibitors), By Distribution Channel (Hospital pharmacies, Retail Pharmacies, Online Pharmacies) and Geography  

Narcolepsy Treatment Market size was valued at USD 3.2 billion in 2022 and is poised to grow at a CAGR of 9.8% from 2023-2029. Narcolepsy is a lifelong sleeping disorder that makes you feel immensely tired sometimes with uncontrollable sudden sleep attacks in severe cases. It is a disabling condition that is characterized by three different symptoms such as excessive daytime cataplexy, sleepiness, and irresistible sleep episodes, fluctuating automatic behaviors. Narcolepsy generally begins between 15 to 25 years and it can be evident at any age. The narcolepsy treatment market is untreated and undiagnosed in many cases. Narcolepsy is the 3^rd most common sleeping disorder which affects a large group of the population. The prevalence rate of narcolepsy is substantially lower in Israel i.e. 1 in 500,000 people and considerably high in Japan i.e. 1 in 600 in comparison with U.S. according to the narcolepsy network. Narcolepsy is not curable but can be treated with drugs like dextroamphetamine, methylphenidate etc. to reduce sleep attacks. Mergers and acquisitions, collaborations, and expansions to untapped geographies are the growth strategies that are adopted by the market players to enhance market growth and to improve their product portfolio. Several voluntary organizations across the world such as Wake up Narcolepsy, Narcolepsy Network, American Sleep Association, and European Narcolepsy Network are actively involved in spreading awareness regarding sleeping disorders and their associated symptoms like EDS, sleep paralysis, and cataplexy.

Narcolepsy Treatment Market Key Developments:  

• In January 2017, Jazz pharmaceuticals received U.S.FDA approval for the first generic version of Xyrem to treat narcolepsy patients.
• In September 2016, Ligand Pharmaceuticals out-licenses 4 development programs to Seelos Therapeutics, that including its H3 receptor antagonist program for narcolepsy, Aplindore program for various CNS disorders, CRTH2 antagonist program for respiratory disorders, Captisol enabled acetaminophen program for fever and pain management.